JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 80 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.45 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $223 | +52.7% | 120,810 | -8.0% | 0.00% | – |
| Q4 2022 | $146 | -99.9% | 131,385 | +13.3% | 0.00% | – |
| Q3 2022 | $272,000 | -43.1% | 115,954 | -26.5% | 0.00% | – |
| Q2 2022 | $478,000 | -53.4% | 157,679 | -1.0% | 0.00% | – |
| Q1 2022 | $1,025,000 | -10.2% | 159,270 | -2.3% | 0.00% | – |
| Q4 2021 | $1,141,000 | -12.4% | 163,037 | -2.4% | 0.00% | – |
| Q3 2021 | $1,302,000 | +22.9% | 167,060 | +7.3% | 0.00% | – |
| Q2 2021 | $1,059,000 | -18.1% | 155,761 | +23.7% | 0.00% | – |
| Q1 2021 | $1,293,000 | +48.3% | 125,923 | +1.0% | 0.00% | – |
| Q4 2020 | $872,000 | +52.7% | 124,633 | +78.0% | 0.00% | – |
| Q3 2020 | $571,000 | +18.2% | 70,035 | +0.1% | 0.00% | – |
| Q2 2020 | $483,000 | +49.5% | 69,999 | +2.9% | 0.00% | – |
| Q1 2020 | $323,000 | -36.3% | 68,036 | +17.2% | 0.00% | – |
| Q4 2019 | $507,000 | +83.7% | 58,075 | -29.9% | 0.00% | – |
| Q3 2019 | $276,000 | -60.2% | 82,838 | -40.9% | 0.00% | – |
| Q2 2019 | $693,000 | – | 140,117 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BML Capital Management, LLC | 1,087,961 | $2,012,728 | 1.74% |
| Opaleye Management Inc. | 2,880,000 | $5,328,000 | 1.60% |
| TANG CAPITAL MANAGEMENT LLC | 5,300,087 | $9,805,161 | 1.46% |
| Ardent Capital Management, Inc. | 923,463 | $1,708,407 | 1.23% |
| Beryl Capital Management LLC | 610,831 | $1,130,037 | 0.89% |
| Arena Investors LP | 610,639 | $1,129,682 | 0.88% |
| Omega Fund Management, LLC | 275,513 | $509,699 | 0.33% |
| Deep Track Capital, LP | 4,259,653 | $7,880,358 | 0.32% |
| PenderFund Capital Management Ltd. | 246,310 | $616 | 0.19% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 425,100 | $786,435 | 0.15% |